Table 4. Grades of documented cetuximab specific AEs.
| All cohort (%) (n = 61) |
XELOX-Cet (%) (n = 26) | XELIRI-Cet (%) (n = 35) |
|
|---|---|---|---|
| Infusion reaction All grades Grade I Grade II Grade III Grade IV |
1 (1.6) 0 0 1 (1.6) 0 |
1 (3.8) 0 0 1 (3.8) 0 |
0 0 0 0 0 |
| Skin rash All grades Grade I Grade II Grade III Grade IV |
38 (62.3) 12 (19.7) 20 (32.8) 6 (9.8) 0 |
20 (76.9) 4 (15.4) 13 (50) 3 (11.5) 0 |
18 (51.4) 8 (22.9) 7 (20) 3 (8.6) 0 |
| Pruritus All grades Grade I Grade II Grade III Grade IV |
27 (44.3) 15 (24.6) 12 (19.7) 0 0 |
14 (53.8) 6 (23.1) 8 (30.8) 0 0 |
13 (37.1) 9 (25.7) 4 (11.4) 0 0 |
| Diarrhoea All grades Grade I Grade II Grade III Grade IV |
29 (47.5) 11 (18) 11 (18) 7 (11.5) 0 |
14 (53.8) 3 (11.5) 6 (23.1) 5 (19.2) 0 |
15 (42.9) 8 (22.9) 5 (14.3) 2 (5.7) 0 |
| Fatigue All grades Grade I Grade II Grade III Grade IV |
30 (49.2) 14 (23) 13 (21.3) 3 (4.9) 0 |
16 (61.5) 9 (34.6) 7 (26.9) 0 0 |
14 (40) 5 (14.3) 6 (17.1) 3 (8.6) 0 |